NewAmsterdam Pharma: Late‑Stage Oral Therapies Targeting Cardiovascular & Metabolic Health
NewAmsterdam Pharma Co NV
2 minutes to read
NEWAMSTERDAM PHARMA CO NV
NewAmsterdam Pharma’s Stock Climbs 51.9% YTD Amid Strong Therapeutic Potential
NewAmsterdam Pharma (NAMSW) delivers a 51.9% YTD rally by pioneering oral small‑molecule therapies for cardiovascular and metabolic diseases, promising long‑term growth despite current negative earnings.
2 minutes to read
NewAmsterdam Pharma’s BROADWAY Trial Shows Promise in Alzheimer’s Treatment
NewAmsterdam Pharma Co NV has emerged as a potential game-changer in Alzheimer’s treatment with positive results from its BROADWAY clinical trial, offering a beacon of hope for millions affected by the disease.
3 minutes to read
Analyst Confidence Soars for NewAmsterdam Pharma Amid Positive Ratings from Cantor Fitzgerald and RBC Capital
NewAmsterdam Pharma Co NV has seen a surge in analyst confidence with two major financial institutions, Cantor Fitzgerald and RBC Capital, issuing positive ratings for the company’s stock.
2 minutes to read
Newamsterdam Pharma Co NV to Showcase Innovations at Global Healthcare Conference
Newamsterdam Pharma Co NV, a late-stage biopharmaceutical company, is set to present at the 2025 RBCCM Global Healthcare Conference, showcasing its oral small molecule therapies for cardiovascular and metabolic diseases.
2 minutes to read